HMDCFHUTCHMED (China) Ltdvs its industry peers
A metric-by-metric comparison of HUTCHMED (China) Ltd against Pharmaceutical Preparations — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| 기업 | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HMDCF본 종목 | — | — | — | — | -13.0%#2 | 1111.0%#1 | -7.1%#2 | 36.9%#1 | 0.0%#2 | — | — | — |
| GSK | $216.6B#1 | — | — | — | — | — | — | — | — | — | 24.6%#3 | — |
| HCM | $12.0B#2 | 26.4x#1 | 9.7x#1 | 21.8x#1 | -13.0%#2 | 1111.0%#1 | -7.1%#2 | 36.9%#1 | 0.0%#2 | — | -21.5%#4 | — |
| HELP | $267M#6 | — | — | — | — | — | — | — | — | — | 106.3%#1 | — |
| HSTC | — | — | — | — | — | -0.8%#5 | — | -11.8%#4 | — | — | — | — |
| HYFT | $64M#8 | — | — | — | — | — | — | — | — | — | -27.3%#6 | — |
| IFRX | $152M#7 | — | — | — | — | — | — | — | — | — | 52.2%#2 | — |
| IMMP | $417M#3 | — | — | — | — | — | — | — | — | — | -83.1%#9 | — |
| IMRN | $278M#5 | — | — | — | — | — | — | — | — | — | -34.6%#7 | — |
| IMRX | — | — | — | — | -100.0%#4 | 8.2%#4 | — | -29.4%#5 | — | — | -50.2%#8 | — |
| INBP | — | — | — | — | 8.0%#1 | 621.4%#3 | 3.7%#1 | 4.3%#3 | 6.0%#1 | 7#1 | — | — |
| INCR | $312M#4 | — | — | — | — | — | — | — | — | — | -26.8%#5 | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2834). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Table built 2026-09-18.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice